Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (1)
  • Open Access

    REVIEW

    Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas

    ASPASIA MANTA1, SPYRIDON KAZANAS2, STEFANOS KARAMAROUDIS3, HELEN GOGAS2, DIMITRIOS C. ZIOGAS2,*

    Oncology Research, Vol.30, No.5, pp. 211-219, 2022, DOI:10.32604/or.2022.026913 - 03 February 2023

    Abstract Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation. These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options. Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis… More >

Displaying 1-10 on page 1 of 1. Per Page